Global Oncology and Radiopharmaceuticals Markets Poised for Strong Growth Through 2035

The global oncology drugs market is undergoing a structural transformation from a chemotherapy-dominated paradigm to a diversified portfolio where targeted therapies, immunotherapies, and cell-based treatments command increasing share. Global cancer incidence is projected to rise from approximately 20 million new cases in 2022 to over 30 million by 2035, providing a strong epidemiological tailwind for market expansion. Meanwhile, the global radiopharmaceuticals market is expected to reach $21.8 billion by 2033, driven primarily by cancer care applications.

According to market analysis, the oncology drugs market is expected to grow at a compound annual growth rate of approximately 8-10% in nominal terms from 2026 to 2035. The shift toward targeted therapies is underpinned by advances in genomic profiling, biomarker identification, and immuno-oncology, which have expanded treatment options across a broad spectrum of solid tumors and hematological malignancies. Immunotherapy is projected to potentially exceed 40% of total oncology drug sales by 2035, while chemotherapy's share declines to below 20%. The pipeline remains robust, with over 2,000 oncology compounds in clinical development globally, many targeting novel pathways and rare mutations.

Key growth levers include the continued penetration of PD-1/PD-L1 inhibitors into earlier lines of therapy, the ramp-up of bispecific antibodies and antibody-drug conjugates, and the gradual uptake of biosimilars in cost-sensitive regions. Biosimilars are gaining traction in Europe, Japan, and select emerging markets, exerting downward pressure on prices for off-patent biologics. The United States remains the largest single oncology market, but Asia-Pacific, particularly China and India, will contribute the fastest absolute growth due to expanding healthcare infrastructure and rising per capita spending.

Regulatory frameworks are evolving to accommodate accelerated approvals and real-world evidence, while payer models are shifting toward value-based arrangements. Hospital and clinic pharmacies remain the primary point of administration for oncology drugs, accounting for nearly half of global oncology drug consumption by value, reflecting the high cost of infused biologics and the clinical necessity of supervised administration.

In the radiopharmaceuticals segment, cancer care represented the largest share in 2023 at 52.2% of market revenue, driven by wider adoption of personalized medicine and molecular profiling. The market is expected to grow at a 10.6% CAGR through 2033. North America led the market in 2023 with over 40% of global revenue and is expected to retain its position through 2033, supported by strong pharmaceutical infrastructure and established regulatory frameworks. Asia-Pacific is projected to see the fastest growth over the forecast period. By product type, diagnostic radiopharmaceuticals hold the largest share today, while the therapeutic segment is expanding through targeted radionuclide therapies for prostate cancer and neuroendocrine tumors. Technetium-99m remains the leading isotope due to its favorable physical characteristics and formulation compatibility.

Innovations in drug delivery are also advancing neuro-oncology treatment. NeOnc Technologies is conducting a Phase 2a glioblastoma study involving NEO100, which uses an intranasal drug delivery platform designed to overcome the blood-brain barrier—a selective protective membrane that creates one of the largest obstacles in modern medicine because many cancer drugs, antibodies, and therapeutics struggle to penetrate brain tissue effectively. Glioblastoma remains one of the deadliest and most treatment-resistant cancers, with extremely poor survival rates despite surgery, radiation, and chemotherapy. If the intranasal platform demonstrates effective CNS penetration combined with favorable clinical efficacy, the implications could extend beyond a single cancer indication.

Key barriers across the oncology market include the high costs of drug development and implementation, potential side effects, pricing pressures from governments and insurers, and the clinical complexity of resistance mechanisms. The net effect is a market that grows robustly in volume and value, but with increasing divergence between innovative premium-priced therapies and commoditized generics and biosimilars.